May 29- June 2, 2026 | Chicago
ASCO 2026
ASCO is the annual meeting on clinically relevant cancer science.
Peregrion attends to meet oncology development teams evaluating AMS microtracer for mass balance, metabolite profiling, and absolute bioavailability work on oncology assets, including compounds with narrow therapeutic windows.
Activities
1:1 sponsor meetings around the congress.
Attending from Peregrion
Steven Erpelinck (Chief Commercial Officer)
Topics for discussion
• Options to perform microtracer studies as part of early-stage patient studies
• Mass balance and metabolite profiling, absolute bioavailability for oncology assets
• Microtracer study design for compounds with narrow safety margins
• MIST package generation from Phase 1 onwards
• Case studies from across the oncology therapeutic area
Book a meeting with Steven Erpelinck: sales@peregrion.com
